According to researchers, from 2011 to 2020 Part D plans grew significantly more restrictive, rising from an average of about 32% of compounds restricted in 2011 to about 44% restricted in 2020. The prevalence of formulary exclusions also spread fast with Part D plan formularies excluding an average of nearly 45% of brand-name-only...